tetano
Editor, Senior Moderator
Therap Adv Gastroenterol
. 2022 Nov 4;15:17562848221132363.
doi: 10.1177/17562848221132363. eCollection 2022.
COVID-19 is not associated with worse long-term inflammatory bowel disease outcomes: a multicenter case-control study
Simon J Hong[SUP] 1 [/SUP], Sumona Bhattacharya[SUP] 2 [/SUP], Aiya Aboubakr[SUP] 3 [/SUP], Devika Nadkarni[SUP] 4 [/SUP], Diana Lech[SUP] 5 [/SUP], Ryan C Ungaro[SUP] 4 [/SUP], Manasi Agrawal[SUP] 4 [/SUP], Robert P Hirten[SUP] 4 [/SUP], Ruby Greywoode[SUP] 6 [/SUP], Anjali Mone[SUP] 5 [/SUP], Shannon Chang[SUP] 2 [/SUP], David P Hudesman[SUP] 2 [/SUP], Thomas Ullman[SUP] 6 [/SUP], Keith Sultan[SUP] 5 [/SUP], Dana J Lukin[SUP] 3 [/SUP], Jean-Frederic Colombel[SUP] 4 [/SUP], Jordan E Axelrad[SUP] 2 [/SUP]
Affiliations
Abstract
Background: Inflammatory bowel disease (IBD) is not associated with worse coronavirus disease 2019 (COVID-19) outcomes. However, data are lacking regarding the long-term impact of severe acute respiratory syndrome coronavirus 2 infection on the disease course of IBD.
Objectives: We aimed to investigate the effect of COVID-19 on long-term outcomes of IBD.
Design: We performed a multicenter case-control study of patients with IBD and COVID-19 between February 2020 and December 2020.
Methods: Cases and controls were individuals with IBD with presence or absence, respectively, of COVID-19-related symptoms and confirmatory testing. The primary composite outcome was IBD-related hospitalization or surgery.
Results: We identified 251 cases [ulcerative colitis (n = 111, 45%), Crohn's disease (n = 139, 55%)] and 251 controls, with a median follow-up of 394 days. The primary composite outcome of IBD-related hospitalization or surgery occurred in 29 (12%) cases versus 38 (15%) controls (p = 0.24) and on multivariate Cox regression, COVID-19 was not associated with increased risk of adverse IBD outcomes [adjusted hazard ratio (aHR): 0.84, 95% confidence interval [CI]: 0.44-1.42]. When stratified by infection severity, severe COVID-19 was associated with a numerically increased risk of adverse IBD outcomes (aHR: 2.43, 95% CI: 1.00-5.86), whereas mild-to-moderate COVID-19 was not (aHR: 0.68, 95% CI: 0.38-1.23).
Conclusion: In this case-control study, COVID-19 did not have a long-term impact on the disease course of IBD. However, severe COVID-19 was numerically associated with worse IBD outcomes, underscoring the continued importance of risk mitigation and prevention strategies for patients with IBD during the ongoing COVID-19 pandemic.
Keywords: COVID-19; inflammatory bowel disease; long term; outcomes.
. 2022 Nov 4;15:17562848221132363.
doi: 10.1177/17562848221132363. eCollection 2022.
COVID-19 is not associated with worse long-term inflammatory bowel disease outcomes: a multicenter case-control study
Simon J Hong[SUP] 1 [/SUP], Sumona Bhattacharya[SUP] 2 [/SUP], Aiya Aboubakr[SUP] 3 [/SUP], Devika Nadkarni[SUP] 4 [/SUP], Diana Lech[SUP] 5 [/SUP], Ryan C Ungaro[SUP] 4 [/SUP], Manasi Agrawal[SUP] 4 [/SUP], Robert P Hirten[SUP] 4 [/SUP], Ruby Greywoode[SUP] 6 [/SUP], Anjali Mone[SUP] 5 [/SUP], Shannon Chang[SUP] 2 [/SUP], David P Hudesman[SUP] 2 [/SUP], Thomas Ullman[SUP] 6 [/SUP], Keith Sultan[SUP] 5 [/SUP], Dana J Lukin[SUP] 3 [/SUP], Jean-Frederic Colombel[SUP] 4 [/SUP], Jordan E Axelrad[SUP] 2 [/SUP]
Affiliations
- PMID: 36348637
- PMCID: PMC9637830
- DOI: 10.1177/17562848221132363
Abstract
Background: Inflammatory bowel disease (IBD) is not associated with worse coronavirus disease 2019 (COVID-19) outcomes. However, data are lacking regarding the long-term impact of severe acute respiratory syndrome coronavirus 2 infection on the disease course of IBD.
Objectives: We aimed to investigate the effect of COVID-19 on long-term outcomes of IBD.
Design: We performed a multicenter case-control study of patients with IBD and COVID-19 between February 2020 and December 2020.
Methods: Cases and controls were individuals with IBD with presence or absence, respectively, of COVID-19-related symptoms and confirmatory testing. The primary composite outcome was IBD-related hospitalization or surgery.
Results: We identified 251 cases [ulcerative colitis (n = 111, 45%), Crohn's disease (n = 139, 55%)] and 251 controls, with a median follow-up of 394 days. The primary composite outcome of IBD-related hospitalization or surgery occurred in 29 (12%) cases versus 38 (15%) controls (p = 0.24) and on multivariate Cox regression, COVID-19 was not associated with increased risk of adverse IBD outcomes [adjusted hazard ratio (aHR): 0.84, 95% confidence interval [CI]: 0.44-1.42]. When stratified by infection severity, severe COVID-19 was associated with a numerically increased risk of adverse IBD outcomes (aHR: 2.43, 95% CI: 1.00-5.86), whereas mild-to-moderate COVID-19 was not (aHR: 0.68, 95% CI: 0.38-1.23).
Conclusion: In this case-control study, COVID-19 did not have a long-term impact on the disease course of IBD. However, severe COVID-19 was numerically associated with worse IBD outcomes, underscoring the continued importance of risk mitigation and prevention strategies for patients with IBD during the ongoing COVID-19 pandemic.
Keywords: COVID-19; inflammatory bowel disease; long term; outcomes.